Henry Han

Cardiologist MBBS, MD, FACC, FESC | Physician-Sci & Researcher MPH | #HeartFailure 🧑‍⚕️| #HFA Committee @escardio | Content Catalyst @TCTMD

[Henry Han @HanCardiomd]

What is current guideline-recommended medical therapy for #HFrEF?

#ESCCongress @escardio

[Eric Topol @EricTopol]

The next frontier for prevention of heart and vascular disease isn't targeting lipids. It's about blocking inflammation. These are some of the ongoing clinical trials @NatureMedicine
https://t.co/DSLMoPFqs7

[Henry Han @HanCardiomd]

#Finerenone in #CKD without #DM : FIND-CKD Trial

📍Finerenone slowed CKD progression in non-diabetic CKD, reducing annual #eGFR decline vs placebo (−3.3 vs −4.0 mL/min/1.73m²/yr; P<0.001).

📍Finerenone ⬇️ kidney/CV events by 23% (HR 0.77, P=0.04), supporting cardiorenal protection beyond eGFR preservation.

📍HyperK+ was more common with finerenone (17.0% vs 13.3%), but treatment discontinuation remained low (1.5%).

https://t.co/gg1xceODGE @NEJM

[EACVI President @EACVIPresident]

🌍✨ A successful and inspiring #EACVI National Society Summit 2026 in Sofia, focused on workflow optimization, automation, standardization, multimodality imaging, and the transformative role of AI in cardiovascular imaging.

Over two days, more than 40 National Society representatives, together with cardiovascular imaging experts, EACVI leaders, and industry partners from across Europe, came together to discuss how we can improve cardiovascular imaging acquisition, reporting, education, research, and patient-centred care through collaboration and innovation.

A heartfelt thank you to the Bulgarian Society of Cardiology for their outstanding hospitality, and special appreciation to Prof Yotov, Prof Petrova, and Prof Bayraktarova for being such gracious hosts and for their commitment to advancing cardiovascular imaging.

We are also grateful to our industry partners for their engagement, support, and valuable contributions to the discussions on innovation, AI-enabled workflows, standardization, and the future of multimodality cardiovascular imaging. Collaboration between clinicians, scientists, and industry will be essential to translate innovation into better patient care.

As always, a special thank you to the EACVI team whose dedication, professionalism, and hard work behind the scenes made this meeting such a success. From planning and coordination to ensuring a seamless experience for all participants, your commitment is deeply appreciated and is fundamental to the continued success of EACVI initiatives.

The enthusiasm, expertise, and collaborative spirit demonstrated throughout the meeting reinforce the strength of our imaging community and the exciting future ahead.

Looking forward to translating these discussions into meaningful actions that will benefit patients worldwide.

#EACVI #CVImaging #echofirst #CardiacCT #whyCMR #ThinkPET #CVNuclear #AIinHealthcare #MultimodalityImaging

@VictoriaDe32503 @denisamuraru @gpontone1 @s_e_petersen @anatimoteo46040 @andgiannopmd @NAjmoneMarsan @rmanka_ @carpenter_jp @PezelT @RFontesCarvalho @alessia_gimelli @bernhard_gerber @DrGEMandoli @Matte_Cameli @EchoSoliman @LunaGargani @AnnaBaritussio @SHS06 @Sarah_Moharem

[Henry Han @HanCardiomd]

#FIND-CKD

Primary Outcome by prespecified subgroups and annual change in #eGFR chronic slope in prespecified subgroups

@NEJM

[Henry Han @HanCardiomd]

#Finerenone in #CKD without #DM : FIND-CKD Trial

📍Finerenone slowed CKD progression in non-diabetic CKD, reducing annual #eGFR decline vs placebo (−3.3 vs −4.0 mL/min/1.73m²/yr; P<0.001).

📍Finerenone ⬇️ kidney/CV events by 23% (HR 0.77, P=0.04), supporting cardiorenal protection beyond eGFR preservation.

📍HyperK+ was more common with finerenone (17.0% vs 13.3%), but treatment discontinuation remained low (1.5%).

https://t.co/gg1xceODGE @NEJM

[Samuel Hume @DrSamuelBHume]

I count 12 abstracts on GLP1s for cancer prevention at ASCO

All of them are observational, and it's clear a proper randomized trial is needed here – two things on that

1. Lilly and Novo are not currently interested in doing it (thanks to @theglpman for helping to figure this out)

2. The first randomized trial is planned (called INSPIRE, from the ECOG-ACRIN research group) – for primary and secondary prevention of breast cancer in 11,000 overweight (non-obese) women, with a 5 year follow-up

[Journal of Cardiac Failure @JCardFail]

In HELIOS-B, vutrisiran slowed renal decline in ATTR-CM: fewer ≥40% eGFR drops vs placebo (12.7% vs 21.2%).

Benefits on CV outcomes were consistent across kidney function, even in advanced CKD.

Improves not just CV outcomes but has renal benefits🫀🧪

https://t.co/Bw3XMvW03l

[Circ: PHO @CircOutcomes]

This study examines cost-effectiveness of SGLT2is and ARNis for heart failure and how cost-effectiveness varies by EF and drug price @JJheart_doc @jasonwasfy @KardiologyKazi @laurapco https://t.co/6YaueClHln

[Gregg Fonarow MD @gcfmd]

@ESC_Journals @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd 🚧 Global gaps in implementation

🎯 Global implementation of quadruple GDMT for HFrEF

➡️

❤️‍🩹 1.2 million ☠️s prevented annually

✅ Overcome inertia to meet the challenge

[European Society of Cardiology Journals @ESC_Journals]

🌍 Heart failure affects &gt; 64 million people worldwide + remains a major global health challenge.
👉This review summarizes the latest data on HF epidemiology, trends, and future challenges.
https://t.co/xJipGll9Or

@EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd

[CNN @CNN]

Microsoft and Mayo Clinic are teaming up tto build an AI model trained specifically on medical data, including records, research and the expertise of the hospital’s clinicians, which they say will help both patients and providers. https://t.co/vxB4Kov8nk

[Henry Han @HanCardiomd]

Venous vascular pharmacology: how does it contribute to #HFpEF?

This review discusses current literature on the vasoactive effects of #EDRF and #EDCF in the venous vs. arterial systems, in both preclinical and clinical models on #HFpEF

https://t.co/2jjJkp38qn

@ESC_Journals

[Henry Han @HanCardiomd]

Venous vascular pharmacology: how does it contribute to #HFpEF?

This review discusses current literature on the vasoactive effects of #EDRF and #EDCF in the venous vs. arterial systems, in both preclinical and clinical models on #HFpEF

https://t.co/2jjJkp38qn @ESC_Journals

[Jennifer Kwan MD PhD @jennkwanMDPhD]

The future of medicine takes center stage June 2 @AJIAorg's AGR event. Join leading voices from academia, biotech, philanthropy, VC + @NBA Champion, @survivorcbs⭐️ &amp;🫀tx recipient @ScotPollard31, as we celebrate the next generation of innovators. 🔬🏀❤️#AmericasGotResearch #AJIA

[Henry Han @HanCardiomd]

Vagal Nerve Stimulation in Patients With #HFrEF : The #ANTHEM-HFrEF Trial

Vagus nerve stimulation in HFrEF showed durable autonomic engagement and a strong safety profile, but failed to significantly reduce cardiovascular death or HF 🏥 (HR 0.84, P=0.115); improvements in symptoms and functional status were encouraging but remain hypothesis-generating.

#JACC @JACCJournals

https://t.co/prfAw6WXgV

[Eric Topol @EricTopol]

Big progress vs cancer, folks.
The kind of event curves from randomized trials that we've not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done. #ASCO26, @ASCO

[EJHF Editor-in-Chief @EJHFEiC]

Baseline characteristics of patients with transthyretin #amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of #eplontersen

#ATTR-CM #EJHF
https://t.co/3ajMR4Imfi

@ESC_Journals @HanCardiomd @GiuseppeGalati_ @AmrAbdin10

[Henry Han @HanCardiomd]

Association of #albuminuria and #RightVentricular free wall strain in #HFpEF and at-risk patients: a cardio-renal interaction in #HFpEF

https://t.co/F67IO2KjAe

@EJHFEiC @ESC_Journals

[Henry Han @HanCardiomd]

What’s new in #HeartFailure ? February 2026

#EJHF @ESC_Journals

https://t.co/XRCW7G64tr

@AlbertoAimo90 @DaniTomasoni_

[Henry Han @HanCardiomd]

Stem-Cell–Derived Biologic Ventricular Assist Tissue in Heart Failure (#BioVAT-HF)

In advanced HF, cardiac remuscularization with #BioVAT was associated with an increase in the target heart wall thickness, #LVEF, and QoL in a small early-stage study.

#NEJM @NEJM

https://t.co/xPeoYsbyIs